Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Basal Cell/prevention & control , Carcinoma, Squamous Cell/prevention & control , Drug Eruptions/prevention & control , Melanoma/drug therapy , Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors , Skin Neoplasms/drug therapy , Adult , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Carcinoma, Basal Cell/chemically induced , Carcinoma, Squamous Cell/chemically induced , Drug Eruptions/etiology , Female , Humans , Imidazoles/administration & dosage , Imidazoles/adverse effects , Indoles/administration & dosage , Indoles/adverse effects , Keratoacanthoma/chemically induced , Keratoacanthoma/prevention & control , Keratoderma, Palmoplantar/chemically induced , Keratoderma, Palmoplantar/prevention & control , Keratosis, Actinic/chemically induced , Keratosis, Actinic/prevention & control , Keratosis, Seborrheic/chemically induced , Keratosis, Seborrheic/prevention & control , Male , Middle Aged , Oximes/administration & dosage , Oximes/adverse effects , Photosensitivity Disorders/chemically induced , Photosensitivity Disorders/prevention & control , Proto-Oncogene Proteins B-raf/antagonists & inhibitors , Pyridones/administration & dosage , Pyrimidinones/administration & dosage , Sulfonamides/administration & dosage , Sulfonamides/adverse effects , Vemurafenib